1. Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
- Author
-
David P. B. Watson, Paolo Martelletti, Josefin Snellman, Charly Gaul, Shannon Ritter, Emma Ramsden, Christian Lucas, Patricia Pozo-Rosich, Institut Català de la Salut, [Pozo-Rosich P] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalees i Dolors Neurològics, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Lucas C] Pain Clinic, Service de Neurochirurgie, Hôpital Salengro, CHU de Lille, 59037 Lille Cedex, France. [Watson DPB] Hamilton Medical Group, Aberdeen AB15 4ZT, Scotland. [Gaul C] Migraine and Headache Clinic Königstein, 61462 Königstein im Taunus, Germany. [Ramsden E] Novartis Pharma AG, 4033 Basel, Switzerland. [Ritter S] Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Pediatrics ,medicine.medical_specialty ,Work productivity ,diagnóstico::pronóstico::resultado del tratamiento::fracaso del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Activities of daily living ,Diagnosis::Prognosis::Treatment Outcome::Treatment Failure [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES] ,burden ,healthcare resource ,migraine ,patient-reported outcomes ,treatment failure ,work productivity ,Population ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Migranya - Tractament ,Burden ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Quality of life ,Healthcare resource ,Health care ,medicine ,education ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES] ,Depression (differential diagnoses) ,Migraine ,Original Research ,education.field_of_study ,Patient-reported outcomes ,business.industry ,Emergency department ,medicine.disease ,Anesthesiology and Pain Medicine ,Treatment failure ,Avaluació de resultats (Assistència sanitària) ,Anxiety ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Migraña; Fracaso del tratamiento; Productividad laboral Migraine; Treatment failure; Work productivity Migranya; Fracàs del tractament; Productivitat laboral Introduction Migraine is consistently ranked as one of the most disabling neurological conditions in the world, often causing a substantial impairment of daily activities and quality of life. It also carries a high economic burden of direct and indirect healthcare costs. Patients with difficult-to-treat migraine often cycle through different preventive therapies, but real-world prospective evidence describing the burden of migraine in patients with prior preventive treatment failure (PPTF) in Europe is limited. In BECOME, we aimed to characterize and assess the prevalence and burden of migraine in patients with PPTF attending specialist headache centers in Europe and Israel. Furthermore, we assessed this burden in pre-specified subgroups based on the frequency of monthly migraine days (MMD) and number of PPTFs. Methods BECOME was a prospective, non-interventional study conducted in two concurrent parts across 17 countries in Europe and Israel. In part 1, patients visiting the centers over a 3-month period were screened for frequency of PPTF, MMD, and other characteristics. In part 2, patients from part 1 with ≥ 1 PPTF and ≥ 4 MMD were enrolled, and impact of migraine on patient-reported outcomes, and healthcare resource utilization (HRU) were examined. Results In part 1 (n = 20,837), 62.2% of patients reported ≥ 1 PPTF. In part 2 (n = 2419), 15.3% of patients reported ≥ 4 PPTF. In part 2, the migraine burden measured by the EuroQoL 5 dimensions 5 level (EQ-5D-5L) questionnaire indicated an impact of at least moderate severity in performing usual activities in 26.5% of patients, pain/discomfort in 51.2%, and 26.1% reported being at least moderately anxious/depressed. Most patients reported a severe impact on daily activities and disability due to migraine. Abnormal Hospital Anxiety and Depression subscale scores of ≥ 11 were observed in 29% (anxiety) and 19.8% (depression) of the population. In part 2, analysis of HRU showed 21.2% patients visited an emergency department and 8.4% were hospitalized for headache/migraine in the past year. Conclusions This study provides real-world evidence of the high personal, social, and HRU burden of migraine in Europe and Israel. This study was funded by Novartis Pharma AG, Basel, Switzerland. The study sponsor participated in the study design, data collection, data review, data analysis and writing of the report. The Rapid Service Fee was funded by Novartis Pharma AG, Basel, Switzerland.
- Published
- 2021